Continuous TAP Blocks: Relative Effects of a Basal Infusion vs. Repeated Bolus Doses

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-02-29

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Single-injection transversus abdominis plane (TAP) blocks have been used to treat postoperative pain, and are become very popular within the United States because of their high analgesic potency and relative ease of placement. Unfortunately, the longest local anesthetic available lasts only 8-12 hours. Continuous TAP blocks-also termed "perineural infusion"-involve bathing the multiple nerves of the abdominal wall in local anesthetic using a percutaneously-inserted perineural catheter inserted just anterior (ventral) and cephalad to the anterior superior iliac spine. For most catheter locations, an infusion is preferred to a single-injection nerve block because the duration of analgesia may be extended to better match the duration of surgical pain. But, unlike brachial plexus, femoral, and sciatic nerve perineural infusion, a continuous basal infusion of local anesthetic does not provide adequate analgesia for TAP catheters. This may be due to the fact that the TAP is a relatively tight space, so it might require a bolus of fluid to adequately spread the perineural local anesthetic to the multiple required nerves (as evidence of this, single-injection TAP blocks are very effective, although with a limited duration). The result is that while single-injection TAP blocks are widely used, TAP catheters have not been adopted. This scenario leaves surgical pain untreated following the resolution of the single-injection TAP block. The recent development of an infusion pump that can automatically deliver repeated bolus doses may allow the spread of local anesthetic to the multiple sensory nerves necessary to provide adequate analgesia, with a duration that better matches postoperative requirements. The investigators therefore propose a randomized, double-masked, controlled trial to determine if delivering local anesthetic as a repeated bolus dose results in improved local anesthetic spread/effects compared with a continuous basal infusion for TAP catheters.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Continuous Transversus Abdominis Plane Nerve Block for Postoperative Analgesia

NCT00944151

Incisional Pain

TERMINATED PHASE4

Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA

NCT02601027

Breast - Female

COMPLETED PHASE3

TAP Block for Postoperative Pain Control

NCT02652156

Pain, Postoperative

TERMINATED PHASE3

Comparative Study of Two Different Techniques to Perform TAP-blocks

NCT02571439

POSTOPERATIVE PAIN

COMPLETED PHASE4

TAPB vs. Caudal for Lower Abdominal Surgery in Children: A Double-Blinded Randomized Controlled Trial

NCT02160821

Anesthesia, Recovery Period

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This investigation will be a randomized, observer-masked, controlled, split-body, human-subjects clinical trial. Of note, the investigators will be using standard-of-care local anesthetics under their FDA approved purpose and do not plan to research a possible change of indication or use of these drugs as part of this research project.

Volunteers will be solicited using the CTRI Research Match and an existing database of volunteers (IRB approved). If a volunteer meets inclusion/exclusion criteria (see Eligibility Criteria) and desires study participation, written, informed consent will be obtained using a UCSD IRB-approved/stamped ICF. A urine pregnancy test will be administered to all women of childbearing age following written informed consent but before any study interventions. This urine test will be administered by CTRI nursing staff using standard, FDA-approved urine pregnancy testing devices.

Perineural catheter insertion: Following written, informed consent, subjects will be admitted to the UCSD CTRI Center for Clinical Research Services (CCR) and have demographic/morphometric data recorded (e.g., age, weight, height). An intravenous line will be placed in an upper extremity, followed by external monitors (pulse oximeter, blood pressure, and EKG), and oxygen by nasal cannula. Sedation will be provided with intravenous fentanyl (50 μg) and/or midazolam (1 mg). Bilateral TAP perineural catheters (FlexBlock, Teleflex Medical, Reading, PA, USA) will be inserted using ultrasound guidance using a technique previously described. To check the perineural catheter placement accuracy, 5 mL of normal saline will be administered via the catheters under ultrasound guidance with the definition of a successful catheter insertion an increase in fluid volume within the TAP (the plane between the transversus abdominis muscle and internal oblique muscle). Inaccurately inserted catheters will be replaced.

Treatment Group Assignment: Subjects will act as their own controls: the right side will be randomized to one of two treatment groups: ropivacaine 0.2% administration as either a basal infusion (8 mL/h) or bolus doses (24 mL administered every 3 hours). The left side will receive the other possible treatment. Randomization will be based on computer-generated codes. Randomization will be in blocks of four. An infusion pump with study infusate will be attached to each of the perineural catheters and initiated at Hour 0. Which side of the participant's body will receive the basal rate and which side will receive bolus volume will depend upon the treatment group assignment but the total dose of local anesthetic is the same for each side.

The tubing from the pumps to the subjects will be gently wound at least 5 rotations and covered with opaque tape, masking which perineural catheter is receiving which treatment (ropivacaine is clear, so the flow through the clear tubing from the tape to the perineural catheters will not be visually distinguishable).

Local Anesthetic Administration: The infusion pump administering the basal infusion will be initiated at Hour 0. The infusion pump administering bolus doses will administer a 24 mL bolus dose every 3 hours beginning at Hour 0. Perineural catheters will be removed after 6 hours (a total of 2 bolus doses).

Food and Drink: Both food and accompanying beverages/water will be provided by the hospital and served by the nursing staff immediately following catheter insertion. Meals will be provided without charge to the study subjects. There is no restriction on oral intake following catheter insertion. Subjects will remain within the CTRI-CCR until catheter withdrawal.

Outcome measurements: At all time points, the right side will be measured first, followed by the left side (subjects in the supine position).

Measurements will be performed at baseline (prior to local anesthetic administration), after 6 hours of administration, and at each hour in between for a total of 7 time points:

* Hour 0 (baseline) just prior to local anesthetic administration
* Hours 1 and 2
* Hour 3, just prior to the scheduled bolus dose at Hour 3
* Hours 4 and 5
* Hour 6

The sensory deficit will be measured using two methods:

* von Frey filaments (mechanical detection threshold)
* Cold roller (cold deficit)

The sensory deficit will be measured along two separate anatomical lines at each time point:

* The mid-axillary "vertical" line (measuring cephalad-caudad effects)
* A transverse "horizontal" line passing through the anterior superior iliac spine (measuring anterior-posterior effects)

Statistical analysis: The investigators' calculations are focused on the primary hypothesis that when using transversus abdominis plane (TAP) block perineural catheters, providing local anesthetic in repeated bolus doses increases the cephalad-caudad local anesthetic effects compared with a basal-only infusion of the same volume and dose of local anesthetic. To measure cephalad-caudad local anesthetic effects, we will measure the cephalad-caudad sensory deficit to cold temperature in centimeters along the mid-axillary line. The primary end point will be this measurement after 6 hours of local anesthetic administration (6 hours of a continuous basal infusion or 2 bolus doses at 3-hour increments, the last being 3 hours prior to the measurement of the primary endpoint). Each subject will act as their own control with each side receiving a different treatment. Normality of distribution will be determined using the Shapiro-Wilk normality test (Prism 6, GraphPad, San Diego, California). For normally distributed data, comparisons for parametric and nonparametric data will be tested using the t-test or Mann-Whitney test and presented as mean (SD) or median \[interquartile\], respectively. Nominal data will be analyzed using the Pearson Chi square test. P\<0.05 will be considered significant.

Sample size estimation: With 21 evaluable subjects we will have 80% power at the 0.05 significance level to detect the superiority of the administration of local anesthetic as repeated bolus doses as compared with a continuous basal infusion at Hour 6 (primary outcome). Using an expected standard deviation of 7 cm for the primary endpoint, and given a 2-sided Type I error protection of 0.05 and power=0.80, approximately 21 subjects in each treatment arm will be required to detect a difference between treatment group means of 6 cm. Since this is a split-body study design and each subject will have one of each treatments on opposite sides of the body, 21 subjects total will produce 21 subjects in each treatment arm. The investigators chose 6 cm as a detectable treatment difference because a 3 cm distance is approximately equivalent to the width of one dermatome, and the vast majority of anesthesiologists would consider a 2-dermatome difference clinically significant. To allow for a larger-than-anticipated standard deviations, smaller-than-anticipated difference between treatment means, drop out subjects, or failed catheters, the investigators will enroll a total of 24 subjects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This is a split-body study in which each study subject receives both treatments: one on each side of the body. Which treatment is applied to which side of the body is randomized (and masked).

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

The only individual aware of the treatment group assignments is the investigational pharmacist who has no interaction with the study subjects. Treatment group assignments were released by the investigational pharmacy only after completion of data collection.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RIGHT side BOLUS and left side basal

Bilateral transversus abdominis catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as two separate bolus doses of 24 mL each: one at time point zero and one 3 hours later. For the left catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours

Group Type EXPERIMENTAL

Bolus

Intervention Type DRUG

A transversus abdominis catheter was inserted and ropivacaine 0.2% administered as two separate bolus doses of 24 mL each: one at time point zero and one 3 hours later.

Basal

Intervention Type DRUG

A transversus abdominis catheter was inserted and ropivacaine 0.2% administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours.

RIGHT side BASAL and left side bolus

Bilateral transversus abdominis catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours. For the left catheter, the ropivacaine was administered as two separate bolus doses of 24 mL each: one at time point zero and one 3 hours later

Group Type ACTIVE_COMPARATOR

Bolus

Intervention Type DRUG

A transversus abdominis catheter was inserted and ropivacaine 0.2% administered as two separate bolus doses of 24 mL each: one at time point zero and one 3 hours later.

Basal

Intervention Type DRUG

A transversus abdominis catheter was inserted and ropivacaine 0.2% administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bolus

A transversus abdominis catheter was inserted and ropivacaine 0.2% administered as two separate bolus doses of 24 mL each: one at time point zero and one 3 hours later.

Intervention Type DRUG

Basal

A transversus abdominis catheter was inserted and ropivacaine 0.2% administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

automatic intermittent bolus doses continuous basal infusion

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. healthy volunteers weighing more than 45 kg;
2. must be willing to have bilateral transverses abdominis plane nerve block catheters be placed with subsequent ropivacaine administration and sensory testing for 6 hours

Exclusion Criteria

1. BMI greater than 40 (BMI=weight in kg/ \[height in meters\];
2. regular opioid use within the previous 2 months;
3. previous participation within the same study;
4. allergy to study medications;
5. known renal insufficiency (creatinine \> 1.5 mg/dL);
6. pregnancy;
7. incarceration; and
8. any known neuro-muscular deficit of either abdominal wall.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes